KR20130105003A - Cosmetic composition for improving atopic skin comprising herb extract fermented in bamboo cylinder and manufacturing method thereof - Google Patents
Cosmetic composition for improving atopic skin comprising herb extract fermented in bamboo cylinder and manufacturing method thereof Download PDFInfo
- Publication number
- KR20130105003A KR20130105003A KR1020120027060A KR20120027060A KR20130105003A KR 20130105003 A KR20130105003 A KR 20130105003A KR 1020120027060 A KR1020120027060 A KR 1020120027060A KR 20120027060 A KR20120027060 A KR 20120027060A KR 20130105003 A KR20130105003 A KR 20130105003A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- cosmetic composition
- bamboo
- fermented
- extract
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 235000017166 Bambusa arundinacea Nutrition 0.000 title claims abstract description 45
- 235000017491 Bambusa tulda Nutrition 0.000 title claims abstract description 45
- 241001330002 Bambuseae Species 0.000 title claims abstract description 45
- 235000015334 Phyllostachys viridis Nutrition 0.000 title claims abstract description 45
- 239000011425 bamboo Substances 0.000 title claims abstract description 45
- 239000000284 extract Substances 0.000 title claims abstract description 40
- 239000002537 cosmetic Substances 0.000 title claims abstract description 32
- 206010003645 Atopy Diseases 0.000 title claims description 35
- 238000004519 manufacturing process Methods 0.000 title description 9
- 238000000034 method Methods 0.000 claims abstract description 14
- 235000016709 nutrition Nutrition 0.000 claims abstract description 13
- 239000006071 cream Substances 0.000 claims abstract description 11
- 239000006210 lotion Substances 0.000 claims abstract description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 235000015097 nutrients Nutrition 0.000 claims abstract description 3
- 238000009472 formulation Methods 0.000 claims description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 230000007760 free radical scavenging Effects 0.000 claims description 19
- 238000000855 fermentation Methods 0.000 claims description 17
- 230000004151 fermentation Effects 0.000 claims description 17
- 230000003020 moisturizing effect Effects 0.000 claims description 17
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 16
- 235000013399 edible fruits Nutrition 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 230000006872 improvement Effects 0.000 claims description 9
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 7
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 7
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 229940010454 licorice Drugs 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- 230000032683 aging Effects 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- 241000235070 Saccharomyces Species 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 244000105624 Arachis hypogaea Species 0.000 claims 1
- 244000018436 Coriandrum sativum Species 0.000 claims 1
- 240000004670 Glycyrrhiza echinata Species 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 230000008020 evaporation Effects 0.000 claims 1
- 239000007791 liquid phase Substances 0.000 claims 1
- 235000020232 peanut Nutrition 0.000 claims 1
- 238000000638 solvent extraction Methods 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 abstract description 11
- 201000008937 atopic dermatitis Diseases 0.000 abstract description 10
- 206010012438 Dermatitis atopic Diseases 0.000 abstract description 9
- 239000012141 concentrate Substances 0.000 abstract description 7
- 241000411851 herbal medicine Species 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 5
- 241001061264 Astragalus Species 0.000 abstract description 2
- 235000006533 astragalus Nutrition 0.000 abstract description 2
- 210000004233 talus Anatomy 0.000 abstract description 2
- 239000000052 vinegar Substances 0.000 abstract description 2
- 235000021419 vinegar Nutrition 0.000 abstract description 2
- 241000220485 Fabaceae Species 0.000 abstract 1
- 235000002262 Lycopersicon Nutrition 0.000 abstract 1
- 241000227653 Lycopersicon Species 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 27
- 230000000694 effects Effects 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 17
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 8
- 208000003251 Pruritus Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 241000202807 Glycyrrhiza Species 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 229940114079 arachidonic acid Drugs 0.000 description 6
- 235000021342 arachidonic acid Nutrition 0.000 description 6
- -1 cinephrine Chemical compound 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 235000006721 Morus bombycis Nutrition 0.000 description 5
- 244000293610 Morus bombycis Species 0.000 description 5
- 241000124033 Salix Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000013566 allergen Substances 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229930182470 glycoside Natural products 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 235000005979 Citrus limon Nutrition 0.000 description 4
- 244000131522 Citrus pyriformis Species 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 240000000249 Morus alba Species 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 235000008708 Morus alba Nutrition 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 235000006040 Prunus persica var persica Nutrition 0.000 description 3
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 239000012676 herbal extract Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 3
- 229940120668 salicin Drugs 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 2
- 241000193388 Bacillus thuringiensis Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000544043 Blyxa aubertii Species 0.000 description 2
- HJXMNVQARNZTEE-UHFFFAOYSA-N Butylphthalide Chemical compound C1=CC=C2C(CCCC)OC(=O)C2=C1 HJXMNVQARNZTEE-UHFFFAOYSA-N 0.000 description 2
- PKRPFNXROFUNDE-LLVKDONJSA-N Byakangelicin Chemical compound O1C(=O)C=CC2=C1C(OC[C@@H](O)C(C)(C)O)=C1OC=CC1=C2OC PKRPFNXROFUNDE-LLVKDONJSA-N 0.000 description 2
- 241000555712 Forsythia Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 229940097012 bacillus thuringiensis Drugs 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 210000003323 beak Anatomy 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 208000027499 body ache Diseases 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229930013686 lignan Natural products 0.000 description 2
- 235000009408 lignans Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010422 painting Methods 0.000 description 2
- VHQQPFLOGSTQPC-UHFFFAOYSA-N pentatriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC VHQQPFLOGSTQPC-UHFFFAOYSA-N 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 210000004706 scrotum Anatomy 0.000 description 2
- PHVSWPDOXIQPTN-UHFFFAOYSA-N sedanonic acid Chemical compound CCCCC(=O)C1CCCC=C1C(O)=O PHVSWPDOXIQPTN-UHFFFAOYSA-N 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- ULSUXBXHSYSGDT-UHFFFAOYSA-N tangeretin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 ULSUXBXHSYSGDT-UHFFFAOYSA-N 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241001330024 Bambusoideae Species 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 241000548268 Citrus deliciosa Species 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- UXDIXFDKSPCUIX-AXFHLTTASA-N Cnidilide Chemical compound C1=CCC[C@@H]2[C@H](CCCC)OC(=O)[C@@H]21 UXDIXFDKSPCUIX-AXFHLTTASA-N 0.000 description 1
- 241000533367 Cnidium officinale Species 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 206010014198 Eczema infantile Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 241001198924 Forsythia koreana Species 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N Glycerol trihexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 241000282596 Hylobatidae Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000301123 Morus cathayana Species 0.000 description 1
- 241000334246 Morus mongolica Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- UPJFTVFLSIQQAV-KOLCDFICSA-N Neocnidilide Chemical compound C1CC[C@H]2[C@H](CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-KOLCDFICSA-N 0.000 description 1
- UPJFTVFLSIQQAV-UHFFFAOYSA-N Neocnidilide Natural products C1CCC2C(CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 1
- 235000010710 Nymphaea lotus Nutrition 0.000 description 1
- 244000213382 Nymphaea lotus Species 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000975417 Oscinella frit Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000202052 Poncirus trifoliata Species 0.000 description 1
- 235000000404 Poncirus trifoliata Nutrition 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 244000018795 Prunus mume Species 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241001164575 Salix koreensis Species 0.000 description 1
- MEGPURSNXMUDAE-UHFFFAOYSA-N Scopoline Natural products C1C(O2)CC3N(C)C1C2C3O MEGPURSNXMUDAE-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- IECRXMSGDFIOEY-UHFFFAOYSA-N Tangeretin Natural products COC=1C(OC)=C(OC)C(OC)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 IECRXMSGDFIOEY-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000003023 adrenocorticotropic effect Effects 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- PKRPFNXROFUNDE-UHFFFAOYSA-N biac-angelicin Natural products O1C(=O)C=CC2=C1C(OCC(O)C(C)(C)O)=C1OC=CC1=C2OC PKRPFNXROFUNDE-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229950005197 butylphthalide Drugs 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- QAIPRVGONGVQAS-DUXPYHPUSA-N caffeic acid Natural products OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- UXDIXFDKSPCUIX-UHFFFAOYSA-N condilide Natural products C1=CCCC2C(CCCC)OC(=O)C21 UXDIXFDKSPCUIX-UHFFFAOYSA-N 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000008341 cosmetic lotion Substances 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000035929 gnawing Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000008738 huangbai Substances 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- YDLYQMBWCWFRAI-UHFFFAOYSA-N n-Hexatriacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC YDLYQMBWCWFRAI-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- JZWFDVDETGFGFC-UHFFFAOYSA-N salacetamide Chemical group CC(=O)NC(=O)C1=CC=CC=C1O JZWFDVDETGFGFC-UHFFFAOYSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- MEGPURSNXMUDAE-RLMOJYMMSA-N scopoline Chemical compound C([C@H](O1)C2)[C@@H]3N(C)[C@H]2[C@H]1[C@H]3O MEGPURSNXMUDAE-RLMOJYMMSA-N 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LGWZGBCKVDSYPH-UHFFFAOYSA-N triacontane Chemical compound [CH2]CCCCCCCCCCCCCCCCCCCCCCCCCCCCC LGWZGBCKVDSYPH-UHFFFAOYSA-N 0.000 description 1
- OLTHARGIAFTREU-UHFFFAOYSA-N triacontane Natural products CCCCCCCCCCCCCCCCCCCCC(C)CCCCCCCC OLTHARGIAFTREU-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 항염, 보습 및 프리라디칼 소거 효과를 갖는 지실, 백지, 천궁, 갈근, 연교, 감초, 작약, 상지, 매지, 도지, 괴지, 유지 복합 발효추출물을 유효성분으로 함유하는 아토피 피부염 개선용 화장료 조성물 및 이의 제조방법에 관한 것이다.
본 발명은 생약 원료인 지실 5~22 중량%, 백지 1~15 중량%, 천궁 1~15 중량%, 갈근 1~15 중량%, 연교 5~22 중량%, 감초 5~22 중량%, 작약 1~15 중량%, 상지 5~40 중량%, 매지 1~15 중량%, 도지 1~15 중량%, 괴지 1~15 중량%, 유지 5~40 중량%의 비율로 혼합하고, 이를 극성 및 비극성 용매로 추출 후 여과지로 여과한 후 일정량 감압 농축하고, 이 농축물을 대나무 통 용기에서 고온으로 살균한 후 효모(Saccharomyces cerevisiae)를 첨가하여 20 내지 30℃에서 일정기간(1 내지 7일) 숙성 발효하여 대나무 통 발효 추출물을 제조한다.
본 발명은 상기 복합 대나무 통 발효 추출물을 액상의 중량으로서 0.001% 내지 60%, 바람직하게는 1.0 내지 15.0%의 양으로, 화장수(스킨로션), 영양로션, 영양크림, 마사지 크림, 영양에센스, 클렌져 제형 등의 각종 화장료에 첨가할 수 있다. The present invention relates to a cosmetic composition for improving atopic dermatitis comprising as an active ingredient an extract of Zygomycin, Baekjiae, Baekji, Astragalus, Leguminosae, Lycopersicum, Compositions and methods for their preparation.
The present invention relates to a herbal composition comprising 5 to 22% by weight of a raw material for herbal medicine, 1 to 15% by weight of white paper, 1 to 15% by weight of herbaceous plant, 1 to 15% by weight of Puerariae, 5 to 22% By weight, from 5 to 40% by weight, from 1 to 15% by weight, from 1 to 15% by weight, from 1 to 15% by weight and from 5 to 40% by weight, After filtration through a filter paper, the concentrate was concentrated under reduced pressure, and the concentrate was sterilized at a high temperature in a bamboo container. Then, yeast ( Saccharomyces cerevisiae ) is added and fermented at 20 to 30 ° C for a predetermined period (1 to 7 days) to produce a fermented bamboo vinegar extract.
The present invention relates to a cosmetic (skin lotion), a nutrient lotion, a nutritional cream, a massage cream, a nutritional essence, a cleanser, a lotion or the like in an amount of 0.001% to 60%, preferably 1.0% And can be added to various cosmetics such as pharmaceutical formulations.
Description
본 발명은 보습, 아토피 피부의 개선 효과를 나타내기 위해 지실, 백지, 천궁, 갈근, 연교, 감초, 작약, 상지, 매지, 도지, 괴지, 유지로 구성된 생약원료를 일정량의 극성 또는 비극성 용매로 추출한 후 감압 농축한 뒤 대나무 통을 이용하여 장기간 발효 숙성한 대나무 통 한방 발효 추출물을 유효성분으로 함유하는, 보습효과, 항염효과 및 프리라디칼 소거효과 등에서 우수한 효과를 갖는 아토피 피부 개선 화장료 조성물 및 그의 제조방법에 관한 것이다.The present invention relates to a method for improving the effect of moisturizing and atopic skin, which comprises extracting a herbal medicine raw material composed of Zyseil, Baekji, Astragalus, Puerariae, Licorice, Licorice, Peony, The present invention relates to a cosmetic composition for improving atopic skin and having excellent effects in moisturizing effect, anti-inflammatory effect and free radical scavenging effect, which comprises a fermented bamboo oil fermented extract obtained by fermentation and aging for a long period of time using a bamboo barrel .
일반적으로 아토피(Atopy)란 그리스어가 어원으로 '비정상적인 반응', '기묘한', '뜻을 알 수 없다'라는 의미로서 어원 그대로 아토피성 피부염이란 다양한 원인이 복잡하게 뒤엉켜 발병하고 완화와 재발을 반복하며, 치료가 어려운 피부질환이다.In general, atopy is a Greek word that means 'abnormal response', 'weird', or 'unknown', and as it is, atopic dermatitis is complicated by various causes and causes remission and recurrence. It is a difficult skin disease.
아토피는 아토피 소인이 있는 개인에서 피부, 호흡기 점막, 안점막, 장잠막 등에 나타나는 일련의 알레르기 증상을 말하며, 이러한 아토피 소인(알레르기 체질)은 유전되어 가족적으로 나타나며, 아토피 소인에 의한 알레르기 질환으로 알레르기 피부염, 알레르기성 비염, 천식, 알레르기성 결막염, 아토피성 두드러기 등이 있으며, 이들 질환은 단독 또는 여러 질환이 동시에 나타날 수 있다.Atopy refers to a series of allergic symptoms that appear in the skin, respiratory mucosa, eye mucosa, and intestinal mucosa in individuals with atopic predisposition. These atopic predispositions (allergic constitutions) are inherited and appear to be family. , Allergic rhinitis, asthma, allergic conjunctivitis, atopic urticaria and the like, these diseases may be present alone or several diseases at the same time.
아토피 알레르기의 메커니즘을 보면 알레르겐이 각질층을 통해 침입해서 표피세포에까지 이르게 되면, 백혈구의 일종인 대식세포(Macrophage, 大食細胞)가 이를 포식하여 조각조각 분해하게 된다. 침입한 알레르겐의 양이 많아 대식세포가 다 처리하지 못할 경우에는, 미처 처리하지 못한 알레르겐의 존재에 대한 정보를 같은 백혈구의 일종인 T세포(면역 촉진과 억제의 조절 기능을 맡고 있다)에 보내주고, T세포는 그 정보를 다시 백혈구의 일종인 호산구(호산성 백혈구)에 전하여, 혈중에 널리 분포된 호산구를 알레르겐이 침입한 장소로 불러 모으게 된다. The mechanism of atopic allergy is that when allergens invade through the stratum corneum and reach the epidermal cells, macrophages (macrophages), which are a type of leukocytes, digest them and break them down. If the macrophage is unable to cope with a large amount of invaded allergen, information on the presence of allergens that have not yet been processed is sent to the same white blood cell T cell (responsible for the regulation of immune stimulation and inhibition) , T cells transmit the information to the eosinophil (eosinophilic leukocyte), a kind of white blood cell, and collect eosinophils, which are widely distributed in the blood, into the place where the allergen has invaded.
이때에 환부에 집적(모여 쌓임)된 호산구가 화학전달물질(활성산소)을 과잉으로 방출시킴으로 인하여 염증이 일어나게 되는데, 이것이 바로 알레르기 반응의 원인이 된다.At this time, eosinophils accumulated in the lesion cause inflammation due to excessive release of the chemical transfer substance (active oxygen), which is the cause of the allergic reaction.
아토피 피부염(태열)의 증상은 심한 가려움증을 가지며, 급성기에는 피부가 가렵고, 붉어지거나 붓거나 좁쌀처럼 돋아 오르거나, 작은 물집이 잡히거나 습하고 딱지가 앉거나 하며, 만성기에는 가렵고, 피부가 딱딱하거나 두꺼워지거나 줄이 가거나 쌀가루 같은 비늘이 앉거나 검어지거나 또는 희게 탈색되거나 하는 모양을 보인다. Symptoms of atopic dermatitis (severe fever) have severe itching. In acute phase, the skin becomes itchy, reddened, swollen, bloomed, blistered, blistered, damp, and itchy in the chronic phase and hard or thick Or scales such as rice flour are sitting, blackened, or whitened.
대개 아토피 피부염은 흔히 태열이라 부르는 영아기 습진으로부터 시작한다. Atopic dermatitis usually begins with an infantile eczema, often called a fever.
현재 사용하고 있는 치료약 중 스테로이드제(부신피질호르몬제)는 크게 소염작용과 면역억제 작용이 있으며 효과가 우수하다. Steroids (corticosteroids) among the currently used medicines have largely anti-inflammatory and immunosuppressive properties and are excellent in their effectiveness.
주의해야할 점은 스테로이드제의 부작용이다. A caveat is the side effects of steroids.
장기간 바르면 바른 부위의 피부에 털이 나고 피부가 위축될 수 있으며, 피부색소가 적어지고 세균의 감염이 생기며, 여드름이 돋고, 피부가 얇아지고 실핏줄이 드러나 아주 흉하게 된다. If applied for a long time, hair on the right area may become hairy, the skin may be shrunk, the skin color becomes less and the bacteria become infected, the acne grows, the skin becomes thinner,
심한 경우에는 호르몬에 의한 전신증상이 나타날 수 있다. In severe cases, hormonal systemic symptoms may occur.
게다가 약을 중지하면 다시 폭발적으로 증상이 심해지므로 이 약을 중지할 수도 없게 된다. In addition, stopping the drug causes the symptoms to explode again, making it impossible to stop the drug.
아토피 피부염의 발병연령이 5세 이전의 유아기에 흔하므로 부신피질의 전신적 투여는 권하지 않고 있다. Systemic administration of the adrenal cortex is not recommended because the age of onset of atopic dermatitis is common in infants before the age of five.
그러므로 호르몬 농도가 아주 적은 스테로이드 연고를 단기간에만 꼭 필요할 때 한꺼번에 많은 양을 바르기보다는 적은 양을 자주 발라야 한다. Therefore, when a steroid ointment with a very low hormone concentration is only needed for a short period of time, it should be applied in small quantities rather than in large quantities at once.
물론 임의로 구해서 사용해서는 안되고 반드시 전문의의 처방을 받아야한다. Of course, you should not use it arbitrarily, but you must be prescribed by a specialist.
항히스타민제는 비만세포에서 히스타민이 유리되지 못하도록 하여 가려운 증상을 경감시키나 임시방편으로 사용하는 것으로 장기간 복용시 불면, 불안, 식욕감퇴 등의 부작용이 있을 수 있다. Antihistamines help prevent the release of histamine in mast cells, thus alleviating the itchy symptoms, but they are used as a temporary measure. There are side effects such as burning, anxiety and loss of appetite when taken over a long period of time.
아토피성 피부염은 그 자체보다 가려워 긁다가 생기는 2차성 세균감염이 더 무서운 병이다. Atopic dermatitis is a more frightening disease with secondary bacterial infections that are more itchy than scratching itself.
항생제는 아토피 치료에 필수적이다. Antibiotics are essential for the treatment of atopy.
아토피 환자의 피부는 장기간 긁고 건조해진 결과로 세균감염이 꼭 따라온다. The skin of atopic patients is accompanied by bacterial infection as a result of prolonged scraping and drying.
아토피 환자의 90%이상이 포도상 구균에 감염되어 있는데 이 균은 환자가 가려움을 참지 못해 긁어서 생기기도 하지만, 최근의 보고에 의하면 이 세균의 외독소가 우리 몸의 면역체계를 자극하여 알레르기를 일으키는 화학물질을 나오게 하여 아토피를 악화시킨다고 한다. More than 90% of atopic patients are infected with Staphylococcus aureus, which is caused by scratching the patient's irritated itch, but recent reports suggest that the bacteria 's exotoxin stimulates the body' s immune system and causes allergic chemicals And atopic dermatitis.
즉, 이 세균 자체가 알레르겐으로 작용한다는 것이다. In other words, the bacteria themselves act as allergens.
따라서 아토피의 치료에는 적절한 항생물질의 사용이 필수적이다. Therefore, the use of appropriate antibiotics is essential for the treatment of atopy.
그 외 약물 치료로 비스테로이드 연고제로는 보습제 종류인데 피부가 좋아진 후에도 계속 사용하는 것이 좋다. Other nonsteroidal ointment is a kind of moisturizer. It is good to continue use even after getting good skin.
그리고 진정시키기 위해 진정제나 신경안정제를 사용하기도 하며, 밤에는 보습을 위해 연고를 바른 후 랩으로 도포 부위를 감싸는 방법도 사용하고 있다.In addition, sedatives and calming agents are used to soothe and at night, ointments are applied for moisturizing, followed by wrapping with a lap.
최근에는 천연물 제제에 대하여 연구가 진행되고 있다. In recent years, research on natural product preparations is underway.
천연물로 조성된 제제는 부작용이 적고, 그 작용이 일반적으로 온화하고 지속적이며 보조성분으로 난용성 성분이 이용성 성분으로 되는 경우가 있으며, 생분해성이 높고 환경 친화적이라고 알려져 있다(KISTI 보고서 2003, 손은수). (KISTI report 2003, Sohn Eun Soo) It is known that a preparation made from a natural product has a low side effect, its action is generally mild and persistent, and an insoluble component as an auxiliary component is used as a usable component. .
이러한 천연물 제제의 예로서, 대한민국 특허등록제 0431076호에는 백급, 자소, 에키나시아 및 발효대두 추출물을 포함하는 아토피 피부의 치유 개선용 화장료 조성물을 개시하고 있고, 대한민국 특허출원공개제 2004-0065126호에는 천연의 영지버섯, 유근피, 감초, 백봉령, 백지마 및 백년초 등으로부터 얻은 한방 식물 추출물을 포함하는 아토피 피부의 치유와 예방에 효과를 갖는 한방 화장료 조성물을 개시하고 있다.As an example of such a natural product preparation, Korean Patent Registration No. 0431076 discloses a cosmetic composition for improving healing of atopic skin comprising a white lotus, a potato, an echinacea and a fermented soybean extract. In Korean Patent Application Publication No. 2004-0065126, And herbal botanical extracts obtained from Ganoderma Lucidum, Ganoderma Lucidum, Lycopersicon esculentum, Lycopersicon esculentum, Bacillus sp.
그리고 대한민국 등록특허 제1081913호에는 길경, 드름, 연교, 치자, 황백, 황금, 황련, 지황, 작약, 천궁, 당귀, 시호, 박하, 우방자 및 천화분으로 구성된 생약추출물을 잎새버섯 균사체 또는 잎새버섯 균사체의 전 배양액을 혼합하여 배양하고, 이 배양액으로부터 잎새버섯 균사체를 제거한 후, 수득된 여과액을 유효성분으로 함유하는 보습, 피부자극 완화, 아토피 개선효과 및 항염효과 등의 피부개선에 우수한 효과를 가지는 발효 생약 추출물을 함유하는 피부 외용재 조성물이 개시되어 있다.In Korea registered patent No. 1081913, a herbal medicine extract composed of Gakyung, Dum, Yeonjong, Gijja, Huangbai, Golden, Huangli, Gianfu, Peony, And the resulting filtrate is used as an effective ingredient for fermentation which has an excellent effect on skin improvement such as moisturizing, skin irritation alleviation, atopic improvement, anti-inflammatory effect, etc. An extracellular solvent composition containing herbal extracts is disclosed.
상기의 특허에서는 잎새버섯을 배양하여 생약 추출물과 당이 혼합된 합성배지에서 배양하는 복잡한 공정에 의하여 발효 생약 추출물은 제조하여야 하는 문제점이 있고, 일반 배양기를 사용함으로써 중금속 등의 2차 오염의 우려가 있었다.In the above-mentioned patent, there is a problem in that a fermented herbal extract must be prepared by a complicated process in which a mushroom is cultured and cultured in a synthetic medium in which a herbal extract and a sugar are mixed, and there is a fear of secondary contamination such as heavy metals there was.
그러나 아직까지도 아토피 치료제의 필수 항목인 보습 효과, 항염, 프리라디칼(Free radical) 소거효과 등을 제공하면서, 부작용이 없는 아토피성 피부질환의 개선용으로서 만족할 만한 천연 제제가 개발되지 못하고 있는 실정이다. However, a natural preparation satisfactory for improving atopic skin diseases without side effects has not yet been developed, while still providing moisturizing effect, anti-inflammation, free radical scavenging effect and the like, which are indispensable components of the atopic treatment agent.
따라서 아토피 치료제의 필수 항목으로 보습효과, 항염효과, 프리라디칼 소거효과 등을 만족시키고, 부작용이 없는 물질의 개발이 절실히 요구되는 실정임을 알 수 있다. Therefore, it is necessary to develop a substance that satisfies the moisturizing effect, anti-inflammatory effect, free radical scavenging effect, and the like, which are essential ingredients of the atopic treatment agent and has no side effects.
본 발명의 상기와 같은 요구에 부응하여, 아토피 피부의 개선을 위하여 우수한 보습효과, 항염효과, 프리라디칼 소거효과 등의 효능이 우수하고 안전성에 문제가 없는 물질을 천연물로부터 추출하여 이를 대나무 통에서 발효시킨 발효 추출물을 제공하는 데 그 목적이 있는 것이다. In response to the above-mentioned demand of the present invention, it has been found that a substance having excellent efficacy such as excellent moisturizing effect, anti-inflammatory effect, free radical scavenging effect and safety is extracted from a natural product for improvement of atopic skin, The present invention provides a fermented extract obtained by the above method.
본 발명의 다른 목적은 이러한 효능을 갖는 발효 추출물을 포함하는 화장료 조성물을 제공하는 것이다.Another object of the present invention is to provide a cosmetic composition comprising a fermented extract having such an effect.
본 발명은 상기 목적을 달성하기 위하여, 아토피의 원인에 대한 근본적 물질을 찾고자 하여 다양한 방법으로 약재를 처리한 결과, 보습 효과, 항염, 프리라디칼(Free radical) 소거효과가 우수한 지실, 백지, 천궁, 갈근, 연교, 감초, 작약, 상지, 매지, 도지, 괴지, 유지를 선택하여 용매로 추출 후 농축하여, 이를 대나무 통에서 미생물을 접종하여 발효시킴으로써 매우 우수한 보습효과, 항염효과, 프리라디칼 소거효과 등의 효능을 나타냄을 알 수 있었으며, 한약재로 쓰이는 지실, 백지, 천궁, 갈근, 연교, 감초, 작약, 상지, 매지, 도지, 괴지, 유지의 추출물을 사용하고, 대나무 통속에서 발효시킴으로써 대나무의 효능 및 이를 사용함에 따라 오염이 없는 천연의 발효 추출물을 생성하여 안전성 문제를 동시에 해결할 수 있다. In order to accomplish the above object, the present invention provides a method for treating atopic diseases, comprising the steps of: (a) It is very effective in moisturizing effect, anti-inflammatory effect, free radical scavenging effect by fermenting microbes in a bamboo tube after fermentation. And bamboo fruit juice extracts were used as the herb extracts of Bacillus spp., Bacillus sp., Bacillus thuringiensis, Puerariae radix, Bacillus thuringiensis, Licorice, By using this, it is possible to solve the safety problem at the same time by generating a natural fermentation extract without contamination.
또한 상기 성분을 화장료 조성물에 유효성분으로 일정농도 이상 배합하여 사람 피부에 직접 도포한 실험 결과에서도 뚜렷한 피부 보습 및 진정효과를 발휘하게 됨을 확인할 수 있었다. In addition, it was confirmed that the skin moisturizing and soothing effect is exhibited even when the above ingredients are mixed with the cosmetic composition at a certain concentration or more as an active ingredient and applied directly to human skin.
이하 본 발명에 사용되는 재료에 대하여 설명한다.Hereinafter, the materials used in the present invention will be described.
지실(枳實, Poncirus trifoliata Rafinesqul)은 탱자나무의 어린 과실을 건조한 것으로, 플라보노이드 배당체와 비타민 C, 아세트산 등의 성분이 함유되어 있으며, 위의 적체를 없애고 가스를 제거하며 위하수와 항문탈출을 낫게 하고, 자궁탈출을 치료하는데 효과가 있다. Poncirus trifoliata Rafinesqul is a dried young fruit of the tangerine tree. It contains flavonoid glycosides, vitamin C, and acetic acid. It eliminates the debris, removes gas, heals the gastrointestinal tract and anal escape , Is effective in treating uterine escape.
그 외, 피부병 치료에 효과가 있고, 약리실험 결과 자궁수축작용, 위장운동, 항진작용, 강심작용, 이뇨작용 등이 있는 것으로 밝혀졌다. In addition, it has been effective in the treatment of dermatosis, pharmacological studies have revealed that there are contractions of the uterus, gastrointestinal motility, hyperactivity, arteriosclerosis and diuretic effect.
또한, 탄제레틴(tangeretin), 노비레틴(nobiletin), 씨네프린, 헤스페리딘 등의 성분을 함유하고 있어서 히스타민 방출을 억제하고, 식욕억제작용 및 콜레스테롤을 억제하는 작용도 있다.It also contains ingredients such as tangeretin, nobiletin, cinephrine, and hesperidin, which inhibit histamine release, inhibit appetite and inhibit cholesterol.
백지(白芷, Angelica Dahuricae Radix)는 산형과(Umbelliferae) 식물인 구릿대를 기원으로 하며 다년생 초본으로 풀이 무성한 저습지나 관목 숲 또는 강가에서 자라며, 가을철에 근부를 채취하여 햇볕에 말려 사용한다. Angelica Dahuricae Radix is a perennial herb that grows in grassy bushes, bushes or riversides, and is harvested in the sun and dried in the sun.
기존의 성분 동정 연구에 의하면 쿠마린(Cumarins), 비악-안겔리신(Byak-angelicin), 오신(Oscine), 강초톡신(Xangthotoxin) 등의 물질이 알려져 있다. According to conventional identification studies, materials such as Cumarins, Byak-angelicin, Oscine, and Xangthotoxin are known.
백지는 전통적으로 열이나 풍으로 머리가 아픈 것을 치료한다고 알려져 있으며 또한 풍증으로 어지러운 것을 낫게 하는데 알약을 만들어 복용한다(본초강목). White paper is traditionally known to treat fever with heat or wind, and it is also made by taking pills to make things worse by the wind.
한방에서는 진통, 지혈, 진정약으로 사용한다. In one room, it is used as analgesic, hemostasis, and sedative.
백지와 관련된 연구를 살펴보면 피지분비 촉진에 의한 피부염 치료(일본 특개평 9-176030), 인체 안정성이 뛰어난 발모 억제제(일본 특개평 10-139639), 온욕 효과를 높인 입욕제(일본 특개평 06-206814) 등이 알려져 있고, 동의보감과 신농본초경에 상기 백지를 고약과 분으로 만들어 얼굴에 바르면 따뜻한 기운을 얼굴 피부로 보내 혈액순환을 촉진하여 안색을 기름지게 윤택하게 하며, 얼굴에 기미와 주근깨, 흉터를 없앤다고 기록하고 있다.Studies related to white paper have shown that treatment of dermatitis by promotion of sebum secretion (Japanese Patent Laid-Open No. 9-176030), hair growth inhibitor having excellent human stability (Japanese Patent Laid-Open Publication No. 10-139639) And it is said that the above blank paper is made into the plaster and the minus in the Dongbuibogam and the sacred Maternity manure, and when it is applied to the face, the warm aura is sent to the face skin to promote the circulation of the blood to make the complexion fertile, and to remove the spots, freckles and scars on the face .
천궁(川芎, Cnidium officinale Makino)은 미나리과의 여러해살이풀로 중국이 원산이며 약용 작물로 재배하며, 높이 30 ~60cm이며, 성분으로는 크니딜라이드(cnidilide), 리구스틸라이드(ligustilide), 네오크니딜라이드(neocnidilide), 부틸프탈라이드(butylphthalide), 세다노닉산(sedanonic acid) 등이 함유된 것으로 알려져 있고, 식물체에 향기가 나는 특징을 가지고 있다. Cnidium officinale Makino is a perennial herb that is native to China and cultivated as a medicinal crop. Its height is 30 to 60 cm and its components are cnidilide, ligustilide, It is known to contain neocnidilide, butylphthalide, and sedanonic acid, and it has a characteristic of smelling plants.
상기 천궁의 뿌리는 불규칙한 결절상의 덩어리로서 직경이 2 내지 7㎝이며 표면은 황갈색으로 거친 주름과 평행으로 융기한 윤절이 여러 개 있으며, 정상부에는 오목한 원형의 줄기 흔적이 있고, 그 단면은 황백색 혹은 회황색인데 황갈색의 유실이 산재해 있고 형성층은 물결 모양의 황문을 이룬다. The root of the cystic mantle is an irregular nodule mass with a diameter of 2 to 7 cm. The surface is yellowish brown with several ridges rising in parallel with rough wrinkles, with concave circular stem marks on the top, It is yellow but yellowish brown is scattered. Formation layer is wavy.
천궁은 한방에서는 그 뿌리줄기를 건조하여 사용하고, 자궁 진정작용과 혈압조절작용, 항균작용, 피부사상균에 대한 억제 작용, 두통, 빈혈, 불임, 월경불순, 냉증 등의 부인병에 사용하였다. 민간에서 좀 예방을 위해 옷장에 넣어두었다(정보섭, 신민교, 향약 대사전).The rootstock was dried and used in oriental medicine, and it was used for gynecological diseases such as uterus sedation, blood pressure control, antimicrobial action, inhibition against dermatophytes, headache, anemia, infertility, menstrual irregularity and poor circulation. I put them in the wardrobe for some prevention in the private sector (Ibsub, Shin Min-gyo, Ambassador's Dictionary).
갈근(葛根, Pueraria lobata Ohwi)은 콩과 식물의 다년생 초본인 칡의 뿌리를 건조한 것으로 한국, 중국, 일본 각 지역의 산에 자생한다. Pueraria lobata Ohwi is a dried perennial herbaceous plant root of the legume plant, and it grows in mountains of Korea, China and Japan.
한의학에서는 칡의 여러 부위를 각각 분류하여, 칡뿌리를 건조한 것을 갈근, 꽃은 갈화, 열매는 갈곡 또는 갈실, 잎은 갈엽, 덩굴은 갈만이라 부르며 질병의 증상 및 치료방법에 따라 각각 다르게 사용하여 왔다. In Chinese medicine, the various parts of the 칡 are classified, and the dried root of 칡 is called root, the flower is brown, the fruit is brown or brown, the leaves are brown, and the vine is brown, and it has been used differently depending on the symptoms and treatment of the disease. .
한방에서 갈근은 기육을 풀어 주는 작용을 하므로 감기 몸살이나 발진성 질환, 항강통 등을 해소할 목적으로 사용되며, 비장과 위장의 기를 상승하게 도와주어 진액을 만들어 갈증을 해소하게 하고 지사시키는 작용을 한다. It is used for relieving cold body aches, digestive diseases, and intestinal tract. It helps the spleen and stomach to rise, so it can help to relieve thirst and make a branch. do.
주요성분으로는 이소플라보노이드인 디옥시미로에스트롤(deoxymiroestrol)과 푸에라린(puerarin)을 다량 함유하고 있다. The major components are deoxymyestrol (deoxymyestrol) and puerarin, which are isoflavonoids.
갈근과 관련한 약리 작용으로는 항 알코올중독(antidipsotropic) 작용, 간 보호 작용, 숙취 억제 작용, 항산화 활성 작용 등이 알려져 있다(정보섭, 신민교, 향약 대사전).Antidipsotropic, hepatoprotective, hangover inhibitory, and antioxidant activities are known as pharmacological actions related to Puerariae.
연교(連翹, Forsythia koreana Nakai)는 물푸레나무과(Oleaceae)에 속하는 개나리의 열매이다. Forsythia koreana Nakai is a fruit of the forsythia belonging to the Oleaceae family.
개나리는 낙엽관목으로 높이는 2~3m이고 가지가 가늘고 길며, 퍼져 있거나 혹은 아래로 드리워져 있고 속이 비어 있다. 꽃은 잎보다 먼저 피는데 1~4송이가 잎에 착생한다. The forsythia is a deciduous shrub with a height of 2 ~ 3m and its branches are thin and long, spread or fallen downward and hollow. Flowers bloom earlier than leaves, and 1 to 4 flowers blossom on leaves.
열매는 좁은 계란형이고 끝에는 짧은 부리가 있으며 완전히 익었을 때는 2조각으로 갈라졌으며, 산야의 황무지에서 자라고, 열매가 익었을 때 또는 완전히 익었을 때 채취하여 햇볕에 말려 쓴다. The fruit is a narrow oval shape with a short beak at the end. When fully ripe, it is split into two pieces. It grows in the wilderness of Sanya, and when the fruit is ripe or fully ripened, it is picked and dried in the sun.
연교의 성분은 리그난(lignan)으로서 악티게닌 등, 리그난 배당체로서 악틴(arctiin) 및 카페인 배당체(caffeic acid glycoside) 등이 알려져 있다. Actinomycetes are known as lignans such as actigenein, lignan glycosides actin and caffeic acid glycosides.
한방에서 소염, 배농 등의 피부질환제로서 사용되며 한국과 중국 등지에서 자생하고 있다(본초강목).It is used as an anti-inflammatory agent for skin diseases such as inflammation and drainage, and is naturally grown in Korea and China.
감초(甘草, Glycyrrhizae Radix)는 콩과에 속하는 다년생초본이며, 유럽감초(Glycyrrhiza glabraL.), 만주감초(Glycyrrhiza uralensis F.) 또는 기타 동속식물의 뿌리와 주출경을 그대로 또는 주피를 제거한 것이다. Glycyrrhizae Radix is a perennial plant belonging to the soybean family, and is the root of the European licorice (Glycyrrhiza glabraL.), Manchuria licorice (Glycyrrhiza uralensis F.) or other herbaceous plants.
감초의 약리작용으로 부신피질 호르몬 작용, 항염 활성증 및 항알레르기 작용, 소화계통에 대한 작용, 해독 작용, 지질대사에 대한 작용, 실험성 황달에 대한 영향, 진해 작용, 진통 및 항경련 작용, 비뇨 및 생식기계통에 대한 작용, 항종양 작용, 기타 체중증가작용, 근력 증강 작용, 혈압 상승 작용, 용혈 작용, 억균작용, 항균작용, 해열작용, 조충에 대한 구충 작용 등이 밝혀졌다. The pharmacological effects of licorice include adrenocorticotropic action, antiinflammatory activity and antiallergic action, action on digestive system, detoxification action, action on lipid metabolism, effect on experimental jaundice, vasopressin action, analgesic and antiepileptic action, And the effects on the reproductive system, antitumor action, other body weight gain, muscle strength, hypertension, hemolysis, insecticidal action, antimicrobial action, antipyretic action,
약용으로 주로 뿌리와 포복경을 이용하며, 약용되는 주성분은 트리테르페노이드(triterpenoid), 사포닌(saponin)인 글리시리진산(glycyrrhizic acid)을 3.63 내지 13.06% 함유하며 그 외 여러 종류의 플라본(flavone) 화합물이 있다(생약학교재편찬회, 생약학, 개정3판(2002), 동명사).Medicinally, mainly roots and apricot are used. The main ingredient used is triterpenoid, glycyrrhizic acid (saponin) in the range of 3.63 to 13.06%, and various kinds of flavone compounds (Genetic Medicine Manual, Genetic Medicine, Revised 3rd Edition (2002), Tongmyung).
작약(芍藥, Paeoniae Radix)은 참작약 및 동속 식물의 뿌리로서 매우 중요한 생약 중의 하나이다. Paeoniae (Paeoniae Radix) is one of the most important medicinal herbs as a root of the medicinal herb and its plants.
잎은 어긋나고, 잎자루는 길며, 2회 삼출 겹잎으로 작은 잎은 타원형이며, 톱니는 없고 꽃은 줄기 끝에 한 개씩 나며, 5, 6월에 흰 꽃이 핀다. Leaves are alternate phyllotaxis, petiole is long, 2 times exudate leaf, small leaf is oval, no sawteeth, flower blooms one at the end of stem, white flowers bloom in 5th and 6th month.
생약으로는 뿌리를 말린 것이며, 생지는 산의 나무 그늘에서 자란다. Herbal medicine is dried root, and the plant grows in the shade of a mountain tree.
우리나라 전국에 분포되어 있으며, 한방에서는 3월과 8월에 땅속줄기를 채취하여 햇볕에 말려 치조, 양혈제, 보혈, 익비, 지통에 사용한다. 한방에서는 수렴완화, 진경, 진통제로서 사용되어 왔으며, 계지가작약가대황탕 등으로 사용되어 왔다. It is distributed all over Korea. In one branch, it is collected in March and August and dried in the sun to be used for alveolar, hematocrit, blood, ejaculation, and till. In one room, it has been used as convergence relief, epidermis, and analgesic.
상지(桑枝, Ramulus Mori)는 뽕나무속 식물의 여린 가지를 말린 것으로, 뽕나무속 식물로는 뽕나무(Morus alba,Linne), 처진 뽕나무(Morus alba for. Peldulls DIPPEL), 산 뽕나무(Morus bombycis, Koidzumi), 꼬리 뽕나무(Morus bombycis var. Caudatifolia), 섬 뽕나무(Morus bombycis var. maritima KOIDZ), 가새 뽕나무(Morus bombycis for. Kase VYKEI), 몽고 뽕나무, 왕 뽕나무, 돌 뽕나무(Morus tiliaefolia, Makino)가 있으며, 이들은 낙엽활엽성의 교목으로 한국의 대부분 지역에 걸쳐 표고 500 - 1,400 m에 수평적으로 분포하며, 산골 마을 부근이나 산기슭에 자생한다.Morus alba, Linus, Morus alba for Peldulls DIPPEL, Morus bombycis, Koidzumi, Morus bombycis and Ramulus Mori are the dried branches of the mulberry plants. ), Morus bombycis var. Caudatifolia, Morus bombycis var. Maritima KOIDZ, Morus bombycis for Kase VYKEI, Mongolian mulberry, Royal mulberry, Morus tiliaefolia, Makino , These are deciduous broad - leaved arboreous trees distributed horizontally at altitudes of 500 - 1,400 m in most parts of Korea, and they grow in the vicinity of mountain villages or at the foot of mountains.
통상적으로 상지는 약간 쓴맛이 나며, 소염, 이뇨, 강장, 발한 및 풍을 제거하는 등의 효능이 있어, 오래전부터 한약재로 쓰이고 있다(대한민국 등록특허 제 230130 호).Generally, the upper limbs are slightly bitter, and they have been used as herbal medicines for a long time because of their efficacy such as anti-inflammation, diuretic, tonic, sweating and removing the wind (Korean Patent No. 230130).
매지(梅枝)는 매화나무 가지로 매화나무(Prunus mume Sieb.Et Zucc)는 잎이 지는 작은 큰키나무(소교목)로서, 달걀 모양의 잎이 어긋나게 붙어있고, 이른 봄 잎이 나기 전에 흰색 또는 붉은 색 꽃이 핀다. Plum tree (Prunus mume Sieb.Et Zucc) is a small leafy tree (small tree) with oval leaves staggered, and before the early spring leaves, white or red The color blossoms.
매화나무의 열매를 매실이라 하며 열매는 둥글고 여물면 노란색을 띤다. The fruit of the plum tree is called the plum, and the fruit is round and yellow when worn.
열매살에는 레몬산, 사과산, 포도산, 호박산, 시토스테롤, 올레아놀산, 세틸알코올, 씨에는 아미그달린이 있으며, 선열매는 레몬산의 원료로도 사용하고, 마른 열매에는 레몬산 19%, 사과산 1.5% 가 들어있으므로 약 10%의 거둠률로 레몬산을 만들 수 있다. There are lemon, malic acid, vinegar, succinic acid, sitosterol, oleic acid, cetyl alcohol and seed amidgalin in the fruit flesh and also used as a raw material of lemon acid. Dried fruit contains 19% of lemon acid and 1.5% of malic acid. You can make lemon acid with a 10% buildup rate.
동의치료에서 청량성 수렴약, 설사멎이약, 열내림약, 기침약, 가래약으로 쓴다(약초의 성분과 이용, 일월서각, 1999, 358).In migraine treatment, it is used as a calming concentrate, diarrhea, fever, cough medicine, and phlegm (herbal ingredients and use, January, 1999, 358).
도지(桃枝)는 복숭아나무 가지로 복숭아 나무는 잎이 지는 작은 큰키나무이다. Togi (peach branch) is a peach tree branch. Peach tree is a small tall tree with leaves.
꽃에는 켐페롤과 그 배당체, 3염기산과 디옥시1염기산이 함유되어 있으며, 잎에는 니트릴 배당체를 함유하고 있고 수증기 증류하면 벤즈알데히드와 시안화수소가 생기며 타닌질이 0.07~0.2% 함유하고 있다. Flowers contain chemperol, its glycosides, tribasic acid and dioxybasic acid, leaves contain nitrile glycosides, and when steam is distilled, benzaldehyde and hydrogen cyanide are formed and 0.07-0.2% tannins are contained.
씨에는 에물신이 약 30%, 아미그달린이 약 1.5% 함유되어 있으며, 나무껍질에는 나린게닌(C15H12O5), 트리아콘탄, 펜타트리아콘탄 등이 있고, 기름 40 내지 50%(주성분은 올레인, 팔미틴, 스테아린)가 함유되어 있다. (C 15 H 12 O 5 ), triacontane, pentatriacontane, etc., and the oil content of oil 40 to 50% ( The main components are olein, palmitin, stearin).
동의치료에서 꽃을 이뇨제, 센 설사약으로 변비치료에 쓰이며, 민간에서는 잎이 붙은 가지를 가마에 넣고 달인 액으로 건포, 습진에 목욕한다. Flowers are used as a diuretic or synergistic therapy in constipation therapy. In the private sector, the leaves are put into a kiln, and the bath is bathed in raisins and eczema.
괴지(槐枝)는 회화나무의 가지로 회화나무(Sophora Japonica L)는 콩과에 속하며, 높이 25m 안팎으로, 한국, 일본, 중국 등지에 분포한다. Jiji (槐 枝) is a branch of a pictorial tree. Sophora Japonica L belongs to the legume, and it is distributed in Korea, Japan, and China, about 25m high.
가지가 퍼지고 작은 가지는 녹색이며 자르면 냄새가 나는 것이 특징이며, 잎은 어긋나고 1회 깃꼴겹잎이다. The branch is spread, the small branch is green, and it is characterized by the smell when it is cut. The leaf is alternate and it is once folded compound leaf.
<향약집성방>에는 종기와 음낭 밑이 축축하고 가려울 때 회화나뭇가지를 물로 달여서 씻으면 효과가 있다고 전한다. It is said that it is effective to wash the branches and branches of the painting with water when it is damp and the under side of the scrotum and the scrotum are itchy.
회화나무의 꽃봉오리를 괴화 또는 괴미라고 하며 열매를 괴실 또는 괴각이라 하는데, 모두 약용으로 한다. The flower bud of a painting tree is called a weeping or gnawing, and the fruit is called a gnarrow or a sacrum.
열매는 협과로 원기둥 또는 염주 모양이며, 과실은 가지 및 나무껍질과 더불어 치질치료에 쓰이기도 하며, 정원수나 목재는 가구재로 이용되기도 한다. Fruits are rounded or rosary in shape and fruits are used in the treatment of hemorrhoids along with branches and bark, and garden or wood is also used as furniture.
한편, 괴화의 알려진 용도로는 동맥경화 및 고협압의 치료 또는 예방이며, 맥주와 종이를 황색으로 만드는데 쓰이기도 한다(대한민국 등록특허 제2011-0004603호).On the other hand, a known use of beak is to treat or prevent arteriosclerosis and hypertension, and may be used to make beer and paper yellow (Korean Patent Registration No. 2011-0004603).
유지(柳枝)는 버드나무 가지로 버드나무(Salix koreensis Andersson)는 버들 또는 뚝 버들이라고도 하며, 껍질에는 탄닌질 3 ~ 10%, 플라본, 아스코르부산, 배당체 살리신(C13H18O7, 녹는점 201.5℃, 물에 풀리고 알코올에 약간 풀리며 에테르에는 풀리지 않는다.)이 있다. Salix koreensis Andersson is also known as willow or weeping will, and the shell contains 3 to 10% of tannin, flavon, ascorbic acid, glycoside salicin (C 13 H 18 O 7 , Point 201.5 ° C, unrolled in water, slightly loosened in alcohol, not dissolved in ether).
살리신은 식물의 부위와 종류에 따라 없거나 5%까지 들어 있다. Salicin is absent or contains up to 5% depending on the area and type of plant.
살리신은 효소에 의하여 살리게닌과 포도당으로 분해된다. Salicin is degraded by enzymes to nin and glucose.
버드나무는 아스피린의 주요작용 성분과 비슷한 성분(Salicyl)을 가지고 있어서 열을 내리게 하고 염증과 통증을 완화하는 작용을 한다. Willow has a component (salicyl) that is similar to the main active ingredient of aspirin, so it acts to relieve fever and relieve inflammation and pain.
그러므로 감기 몸살과 같이 열을 동반하는 가벼운 증상에 그리고 급만성 류마티즘 및 가벼운 증상의 두통과 염증으로 인한 통증을 완화하는 데 좋은 효과가 있으며, 효능이 가장 좋을 때인 2월과 3월 사이에 수확한 버드나무껍질을 이용한다. Therefore, it has a good effect to alleviate the mild symptoms accompanied by fever like cold body aches and pain caused by acute chronic rheumatism and mild symptoms of headache and inflammation, and when it is best when it is harvested between February and March It uses bark.
이러한 버드나무의 효능을 이용한 기술로는 대한민국 특허출원 제10-2008-7000798호 ‘버드나무 추출물, 그 용도, 및 그것을 함유하는 제제’, 대한민국 특허출원 제10-2001-0081882호 ‘버드나무 추출물을 함유하는 비듬 방지용 모발 화장료 조성물’ 등이 있다.Examples of technologies utilizing the efficacy of such willow are Korean Patent Application No. 10-2008-7000798, "Willow tree extract, its use, and formulation containing it", Korean patent application No. 10-2001-0081882 "Willow tree extract And a hair cosmetic composition for preventing dandruff.
대나무는 외떡잎식물 벼목 화본과(벼과, Poaceae) 대나무아과(Bambusoideae)에 속하는 여러해살이식물의 총칭으로, 전 세계적으로 분포하나 주로 열대 지방에서 자라며, 특히 아시아의 계절풍 지대에 흔하며 우리나라에서는 중부 이남과 제주도에 많이 분포하고 있다. Bamboo is a generic term for perennial plants belonging to the bamboo family (Bambusoideae) belonging to the monocotyledonous plant (Poaceae). It grows mainly in the tropics, especially in the seasonal area of Asia. In Korea, It is widely distributed.
대나무는 뿌리에서부터 잎까지 약용으로서 활용도가 높으며 고대문헌 <신봉본초경>에 댓잎은 맛이 쓰고 성질이 차서 해소, 상기, 종양, 해열 및 상충에 효과가 있다고 알려져 있으며, 특히 대나무 기름(죽력)은 아토피, 여드름, 습진, 무좀, 기미, 두피 가려움증, 탈모, 건선 등 각종 피부 트러블에 뛰어난 효과를 가지는 것으로 알려져 있다. Bamboo is widely used as a medicinal product from root to leaf. It is known that the gibbons taste in the ancient literature <Shin Bong Intersection> is effective for the above-mentioned, tumor, fever and confusion. Especially, bamboo oil (bamboo oil) , Acne, eczema, athlete's foot, stinging, itching of the scalp, hair loss, psoriasis, and the like.
그 외에 의학 서적에 기록된 내용을 보면 곽란, 토혈, 거담, 중풍, 당뇨, 두통, 고혈압, 현기증, 신경쇠약, 임신 빈혈, 간질, 불면, 과다음주 및 피로회복 등에 신비한 효능이 있는 것으로 알려져 있다. In addition, the contents recorded in medical books are known to have a mysterious effect on kwakran, gyeolgi, diabetes, headache, hypertension, dizziness, nervous breakdown, pregnancy anemia, epilepsy, insomnia, excessive drinking and fatigue recovery.
이렇듯 대나무의 좋은 효능을 활용하기 위해 대나무 통을 이용한 여러 음식이 개발되어 왔지만, 대나무를 이용하여 쉽게 음용할 수 있는 차의 형태는 대나무 잎을 활용한 죽엽차(竹葉茶)만 있을 뿐이다.In order to utilize the good efficacy of bamboo, various foods using bamboo barrels have been developed. However, there is only bamboo tea using bamboo leaves.
이러한 대나무의 효능을 이용한 기술의 예로서 ‘죽내피 추출물을 함유한 미백화장료’(대한민국 특허출원 제2000-0007943호)와 ‘여드름 피부 개선용 화장료 조성물’(대한민국 특허출원 제 10-2011-0068203), ‘대나무 추출물을 함유하는 신규한 치료용 조성물 및 이 조성물을 포함하는 치료제’(대한민국 특허출원 제10-2000-0052649) 등이 있다.Examples of techniques using the bamboo effect include 'whitening cosmetic ingredient containing bamboo extract' (Korean Patent Application No. 2000-0007943) and 'cosmetic composition for improving acne skin' (Korean Patent Application No. 10-2011-0068203) , A novel therapeutic composition containing bamboo extract, and a therapeutic agent containing the composition (Korean Patent Application No. 10-2000-0052649).
본 발명에서는 상기의 성분들을 지실 5~22 중량%, 백지 1~15 중량%, 천궁 1~15 중량%, 갈근 1~15 중량%, 연교 5~22 중량%, 감초 5~22 중량%, 작약 1~15 중량%, 상지 5~40 중량%, 매지 1~15 중량%, 도지 1~15 중량%, 괴지 1~15 중량%, 유지 5~40 중량%의 비율로 혼합하여 용매 추출한 후 대나무 통에서 발효시켜 발효 추출물을 제조한다.In the present invention, the above-mentioned ingredients are used in an amount of 5 to 22% by weight, 1 to 15% by weight of white paper, 1 to 15% by weight of citron, 1 to 15% by weight of Puerariae, 5 to 22% 1 to 15% by weight of the top layer, 5 to 40% by weight of the top layer, 1 to 15% by weight of the magazine, 1 to 15% by weight of the topical composition, 1 to 15% To produce a fermented extract.
상기와 같은 방법으로 제조된 대나무 통 발효 추출물을 액상으로 0.001 내지 20중량%, 바람직하게는 0.1 내지 10중량% 범위로 화장료에 유효성분으로 포함하는 아토피 피부 개선 화장료 조성물을 제조하는 것이다.The present invention relates to a cosmetic composition for improving atopic skin comprising a bamboo fermentation extract prepared by the above method in an amount of 0.001 to 20% by weight, preferably 0.1 to 10% by weight, as an active ingredient in cosmetics.
본원 발명은 천연의 생약 추출물을 대나무 통에서 발효시킨 천연 발효 생약 추출물로, 인체에 안전하며 우수한 보습효과, 항염효과, 프리라디칼 소거효과를 가짐으로써, 아토피 피부의 개선에 우수한 효과를 가지는 것이다.The present invention is a natural fermented herbal medicine extract obtained by fermenting a natural herbal medicine extract in a bamboo barrel and having excellent moisturizing effect, anti-inflammatory effect and free radical scavenging effect, and is excellent in improvement of atopic skin.
본 발명은 보습효과, 항염효과, 프리라디칼 소거효과를 가짐으로 인해 아토피 피부를 개선할 수 있는 지실, 백지, 천궁, 갈근, 연교, 감초, 작약, 상지, 매지, 도지, 괴지, 유지 복합 대나무 통 한방 발효 추출물을 함유하는 화장료 조성물을 제공하는 것이다.The present invention relates to a bamboo plant which is capable of improving atopic skin due to its moisturizing effect, anti-inflammatory effect and free radical scavenging effect, and which can improve atopic skin, bamboo plant, And to provide a cosmetic composition containing a herbal fermented extract.
구체적으로 본 발명의 지실, 백지, 천궁, 갈근, 연교, 감초, 작약, 상지, 매지, 도지, 괴지, 유지 복합 대나무 통 한방 발효 추출물의 제조방법은 다음과 같다.Specifically, the method for preparing the fermented extracts of the present invention is as follows.
지실 1~22 중량%, 백지 1~15 중량%, 천궁 1~15 중량%, 갈근 1~15 중량%, 연교 1~22 중량%, 감초 1~22 중량%, 작약 1~15 중량%, 상지 1~40 중량%, 매지 1~15 중량%, 도지 1~15 중량%, 괴지 1~15 중량%, 유지 1~40 중량%의 비율로 혼합한다.1 to 22% by weight of ground wax, 1 to 15% by weight of white wax, 1 to 15% by weight of royal wax, 1 to 15% by weight of Puerariae, 1 to 22% 1 to 40% by weight of maggie, 1 to 15% by weight of maggie, 1 to 15% by weight of doze, 1 to 15% by weight of starch and 1 to 40% by weight of oil.
상기 성분을 용매로 추출 후 0.45 ㎛의 여과지로 여과한 후 약 60℃ 전, 후의 온도에서 일정량 감압 농축하고, 이를 대나무 통 용기에 첨가하여 약 110 내지 130℃에서 멸균하고 냉각한 후, Sabouraud dextrose broth (BD Difco 사)를 이용하여 18시간 26℃에서 종균 배양한 효모균(Saccharomyces cerevisiae) 배양액을 접종하고, 20 내지 30℃에서 1 내지 7일 동안 숙성 발효시킨다.The components were extracted with a solvent, filtered through a filter paper having a pore size of 0.45 mu m, and then concentrated under reduced pressure at a temperature of about 60 DEG C before and after the filtration. The filtrate was added to a bamboo container and sterilized at about 110 to 130 DEG C, (BD Difco) for 18 hours at 26 ° C. Saccharomyces cerevisiae culture medium, and fermented at 20 to 30 DEG C for 1 to 7 days.
상기 용매로는 정제수, 에탄올, 부틸렌글리콜 , 프로필렌글리콜, 글리세린, 메탄올로 구성된 그룹으로부터 선택된 하나 또는 둘 이상의 용매를 사용한다.As the solvent, one or two or more solvents selected from the group consisting of purified water, ethanol, butylene glycol, propylene glycol, glycerin and methanol are used.
추출 방법으로는 냉각 콘덴서가 장치되어 용매가 증발되는 것을 방지한 상태에서 50 내지 95℃에서 4 내지 20시간 가열하여 추출하거나, 5 내지 37℃에서 1 내지 15일간 용매에 침적시켜 유효성분을 추출하는 방법을 사용할 수 있다. As the extraction method, extraction is carried out by heating at 50 to 95 ° C for 4 to 20 hours in a state where a cooling condenser is installed to prevent the solvent from being evaporated, or it is immersed in a solvent at 5 to 37 ° C for 1 to 15 days to extract an active ingredient Method can be used.
상기와 같은 방법으로 제조된 대나무 통 발효 추출물을 0.45 ㎛의 여과지로 여과한 후, 액상으로 0.001 내지 20중량%, 바람직하게는 0.1 내지 10중량% 범위로 화장료에 첨가하여 본 발명의 화장료 조성물을 제조하는 것이다.The bamboo fermentation extract prepared in the above manner is filtered through a filter paper having a pore size of 0.45 m and then added to the cosmetic in a liquid form in an amount of 0.001 to 20% by weight, preferably 0.1 to 10% by weight to prepare the cosmetic composition of the present invention .
상기의 함량 범위의 하한치를 벗어나면 그 효과가 현저하게 감소되며, 상한치를 벗어나면 화장료 제형으로 제조하기 곤란하거나, 경제적인 측면에서 바람직하지 아니하다. If the content is out of the lower limit of the above range, the effect is remarkably reduced. If the content is out of the upper limit, it is difficult to prepare cosmetic formulations, or is not preferable from the economical point of view.
본 발명의 화장료로는 화장수(스킨로션), 영양로션, 영양크림, 마사지 크림, 영양에센스, 클렌져 등의 제형으로 사용되며 특별히 여기에 한정하는 것은 아니며, 기타 모발용이나 피부용에 사용될 수 있다.The cosmetic of the present invention may be used as formulations such as lotion (skin lotion), nutrition lotion, nutritional cream, massage cream, nutritional essence, cleanser and the like, and is not limited thereto and may be used for other hair or skin.
이하 본 발명의 구성 및 작용에 대하여 아래의 실시예 및 실험예에서 본 발명의 구체적인 내용을 더욱 상세히 설명하나, 본 발명의 내용이 여기에 한정되지는 않는다.Hereinafter, the present invention will be described in more detail with reference to the following examples and experimental examples, but the present invention is not limited thereto.
실시예Example 1-4. 1-4. 정제수를Purified water 이용한 식물 추출 여과 Used plant extract filtration 농축물Concentrate 제조 Produce
지실, 백지, 천궁, 갈근, 연교, 감초, 작약, 상지, 매지, 도지, 괴지, 유지를 하기 표와 같이 혼합한 후 정제수를 사용하여 추출기로 25℃에서 7일간 숙성한다.The mixture is mixed as shown in the following table and then aged at 25 ° C for 7 days using an extractor using purified water.
숙성 후 400메시 여과포로 여과한 후 0.45 ㎛의 여과지로 여과하고, 60℃에서 감압 농축하여 그 결과를 하기 표 1에 기재하였다.After aging, the mixture was filtered through a 400 mesh filter cloth, filtered through a filter paper having a pore size of 0.45 mu m, and concentrated under reduced pressure at 60 DEG C, and the results are shown in Table 1 below.
[표 1][Table 1]
실시예Example 5. 70% 함수 에탄올 추출 5. 70% functional ethanol extract 농축물의Concentrate 제조 Produce
지실 200g, 백지 100g, 천궁 100g, 갈근 100g, 연교 200g, 감초 200g, 작약 100g, 상지 400g, 매지 100g, 도지 100g, 괴지 100g, 유지 300g을 혼합하여 70% 함수 에탄올 14 kg에 혼합하고 25℃에서 7일간 숙성한다. The mixture was mixed with 14 kg of 70% aqueous ethanol at 25 ° C, and the mixture was stirred at 25 ° C for 10 minutes. Mature for 7 days.
숙성 후 0.45 ㎛의 여과지로 여과하고 60℃에서 감압 농축하여 그 결과를 하기 표 2에 기재하였다.After aging, the mixture was filtered through a filter paper having a pore size of 0.45 mu m and concentrated under reduced pressure at 60 DEG C, and the results are shown in Table 2 below.
[표 2][Table 2]
실시예Example 6, 7과 6, 7 and 비교예Comparative Example 1 내지 3.의 대나무 통을 이용한 Using bamboo containers from 1 to 3 발효물Fermentation product 제조 Produce
실시예 1 내지 5의 농축물을 대나무 통 용기에 첨가하여 121℃에서 30분간 멸균하고 25℃까지 냉각한 후, Sabouraud dextrose broth (BD Difco 사)를 이용하여 18시간 26℃에서 종균 배양한 효모균(Saccharomyces cerevisiae) 배양액을 농축액량의 1/100량을 접종하였다. 이를 26℃에서 3일간 숙성 발효한 후 발효액을 제조하여 그 결과를 표 3에 기재하였다. The concentrates of Examples 1 to 5 were added to a bamboo container and sterilized at 121 ° C for 30 minutes. After cooling to 25 ° C, yeast strain (Sabouraud dextrose broth (BD Difco)) cultured for 18 hours at 26 ° C Saccharomyces cerevisiae were inoculated in 1/100 volume of the concentrated liquid. The fermented broth was fermented at 26 캜 for 3 days, and the fermented broth was prepared.
[표 3][Table 3]
비교예Comparative Example 4. 유리 배양기를 이용한 4. Using a glass incubator 발효물Fermentation product 제조 Produce
실시예 1의 농축물 500g 을 2L 삼각 플라스크에 첨가하여 121℃에서 30분간 멸균하고, 25℃까지 냉각한 후 abouraud dextrose broth (BD Difco 사)를 이용하여 18시간 26℃에서 종균 배양한 효모균(Saccharomyces cerevisiae) 배양액을 농축액량의 1/100의 중량을 접종하였다. 이를 26℃에서 3일간 숙성 발효한 후 발효액을 제조하여 그 결과를 표 4에 기재하였다. 500 g of the concentrate of Example 1 was added to a 2 L Erlenmeyer flask and sterilized at 121 占 폚 for 30 minutes. After cooling to 25 占 폚, yeast strain Saccharomyces cultured for 18 hours at 26 占 폚 using abouraud dextrose broth (BD Difco) cerevisiae culture medium was inoculated at a weight of 1/100 of the concentrated liquid amount. The fermented broth was fermented at 26 캜 for 3 days after aging, and the results are shown in Table 4.
[표 4][Table 4]
실험예Experimental Example 1. One. 프리라디칼Free radical 소거 효능 실험 Erasure efficacy experiment
실시예의 프리라디칼 소거효과를 측정하였으며 각각의 실시예가 갖는 SC50값을 표 4에 고형분 함량을 기준으로 나타내었다.Embodiment, the free radical scavenging activity was measured are shown, based on the solids content of the SC 50 having an example value of each of the embodiments shown in Table 4.
실험 방법Experimental Method
프리라디칼 소거활성 실험법은 1,1-Diphenyl-2-picrylhydrazyl radical(DPPH)을 사용하여 Fujita 등의 방법으로 실시하였다. The free radical scavenging activity was determined by the method of Fujita et al. Using 1,1-diphenyl-2-picrylhydrazyl radical (DPPH).
0.2 mM의 1,1-diphenyl-2-picrylhydrazyl(DPPH, Sigma 사, 미국) 용액 1mL에 각각의 실시예 시료를 각 농도별로 2mL를 첨가하고, 상온에서 10분간 반응 시킨 후, 525nm에서 흡광도를 측정하여 프리라디칼 소거효과(%)를 구하였다. 2 ml of each sample was added to 1 ml of a solution of 0.2 mM of 1,1-diphenyl-2-picrylhydrazyl (DPPH, Sigma, USA), and the reaction was carried out at room temperature for 10 minutes. Then, the absorbance was measured at 525 nm And the free radical scavenging effect (%) was obtained.
이때 블랭크(Blank)는 DPPH 대신 에탄올을 사용하였으며, 대조군은 실험군과 동일한 농도의 아스코르브산(L-ascorbic acid) 2mL을 첨가하였다.Blank used ethanol instead of DPPH, and 2 mL of ascorbic acid (L-ascorbic acid) was added to the control group.
각각의 실시예와 비교예의 프리라디칼 소거활성 SC50을 구하여 표 5에 나타내었다.The free radical scavenging activity SC 50 of each of the Examples and Comparative Examples was determined and shown in Table 5.
프리라디칼 소거활성 SC50은 프리라디칼을 50% 소거하는데 요구되는 추출물의 농도(㎍/㎖)를 표시하는 것으로, 그 결과를 표 4에 나타내었다.The free radical scavenging activity SC 50 represents the concentration (쨉 g / ml) of the extract required for 50% free radical scavenging, and the results are shown in Table 4.
[표 5][Table 5]
상기 표 5에서, 본 발명의 정제수 추출 대나무 통 발효 추출물(실시예 6)은 프리라디칼 소거활성 SC50 값이 7.5 ㎍/㎖의 결과를 보였으며 70% 함수 에탄올 추출 대나무 통 발효 추출물(실시예 7)은 7.3 ㎍/㎖로 비슷한 결과가 나타났다. 이는 대조구로 사용된 아스코르브산과 비교할 때 우수한 효과로 소량으로도 프리라디칼 소거 효과가 뛰어남을 보여주는 것이다.In Table 5, the purified water extracted bamboo tuber fermented extract of the present invention (Example 6) contained free radical scavenging activity SC 50 (7.5 ㎍ / ㎖) and 70% ethanol extract of bamboo tuber fermentation extract (Example 7) showed similar results as 7.3 ㎍ / ㎖. This shows that the free radical scavenging effect is excellent even in a small amount as compared with the ascorbic acid used as a control.
또한 본원 발명의 조성범위를 벗어나는 비교예 1 내지 3에 비하여 프리라디칼 소거 효과가 뛰어나며, 대나무 통을 이용한 발효 추출물(실시예 6, 실시예 7) 이 일반 용기 발효 추출물(비교예 4)보다 우수한 효과를 나타내었다. In addition, the free radical scavenging effect is superior to Comparative Examples 1 to 3 outside the composition range of the present invention, and the fermentation extract using the bamboo barrel (Example 6, Example 7) is superior to the general container fermentation extract (Comparative Example 4) Indicated.
따라서 본 발명의 대나무 통 발효 추출물은 프리라디칼 소거 효과가 뛰어남을 알 수 있다.Therefore, it can be seen that the bamboo fermented extract of the present invention is excellent in free radical scavenging effect.
실험예Experimental Example 2. 항염 실험 2. Anti-inflammatory experiment
상기 실시예의 항염 효과를 알아보기 위하여, 아라키돈산(arachidonic acid)을 이용한 평가법(A. Crummey, G. P. Harper, E. A. Boyle and F. R. Mangan. Inhibition of arachidonic acid-induced ear edema as a model for assessing topical anti-inflammatory compound. Agents and Actions, 1987, 20: 69-76)을 이용하였다.In order to investigate the anti-inflammatory effect of the above examples, a method using an arachidonic acid (A. Crummey, GP Harper, EA Boyle and FR Mangan, Inhibition of arachidonic acid-induced ear edema as a model for assessing topical anti-inflammatory compound. Agents and Actions, 1987, 20: 69-76).
실험 방법 Experimental Method
마우스 좌측 귀를 대조부위, 우측 귀를 시험부위로 하여 시료를 적용하기 전에 에탄올로 귀를 깨끗하게 세척하고, 각각의 실시예의 시료 20 ㎕를 1일 1회 4일간 지속적으로 도포하고 마지막 도포 1시간 후에 좌측 귀에 에탄올을, 우측 귀에는 아라키돈산(Arachidonic acid)을 2㎎/ear 양으로 도포하여 1시간 후 귀의 부종(ear edema) 정도를 마이크로미터로 양쪽 귀를 3회씩 반복 측정하였다.The left ear of the mouse was used as a control site and the right ear was used as a test site. The ear was cleanly washed with ethanol before the sample was applied, and 20 μl of the sample of each example was continuously applied once a day for 4 days and 1 hour after the last application The left ear was coated with ethanol and the right ear was coated with arachidonic acid (2 mg / ear). After 1 hour, ear edema was repeatedly measured three times with micrometer in each ear.
동일한 방법으로 실시예 1 내지 7 및 비교예 1 내지 4의 추출물로 반복 측정하였다.The same method was repeatedly measured with the extracts of Examples 1 to 7 and Comparative Examples 1 to 4.
항염 효과는 아라키돈산(Arachidonic acid) 처리 군을 기준으로 부종억제 정도로 판정하였으며 그 결과를 표 6. 에 나타내었다.The anti-inflammatory effect was judged to be suppression of edema based on arachidonic acid treatment group. The results are shown in Table 6.
※ 억제율(%) = (A ― B) / A × 100 ※ Inhibition rate (%) = (A - B) / A × 100
A : 대조군 귀의 평균두께 (아라키돈산 처리 귀의 두께 - 아라키돈산 비 처리 귀의 두께)A: Mean thickness of control ear (thickness of ear treated with arachidonic acid - thickness of untreated ear of arachidonic acid)
B : 실시예의 도포군 귀의 두께 (시료 처리 귀의 두께 - 시료 비처리 귀 의두께)B: Thickness of the coated ear of the embodiment (thickness of the sample treated ear - thickness of the untreated sample)
[표 6] [ Table 6]
표 6.에서 보듯이, 본 발명의 정제수 추출물의 대나무 통 발효물 1.0% 시료는 32.1%의 염증 억제율을 나타내었고, 70% 함수 에탄올 추출물의 대나무 통 발효물 1.0% 시료는 34.1%의 염증 억제율로 비슷한 효과를 보였으며, 이는 본 발명의 범위를 벗어나는 비교예들에 비하여 현저히 상승된 것으로, 이러한 수치는 의약품 성분으로서 항염 효과가 매우 우수한 물질인 인도메타신(indomethacin)에 비해 크게 떨어지지 않는 우수한 효과를 나타내는 것이다. As shown in Table 6, the 1.0% sample of the bamboo fermented product of the present invention exhibited an inhibition rate of inflammation of 32.1%, and the 1.0% sample of the 70% ethanol extract of the bamboo fermented product had an inflammation inhibition rate of 34.1% These results are remarkably improved compared to the comparative examples which are outside the scope of the present invention. These values are superior to those of indomethacin, which is an excellent anti-inflammatory substance as a pharmaceutical ingredient. .
따라서 본 발명의 대나무 통 발효 추출물은 항염 효과가 뛰어남을 알 수 있다.Therefore, it can be seen that the bamboo fermented extract of the present invention is excellent in anti-inflammatory effect.
실험예Experimental Example 3. 보습실험 3. Moisture Experiment
본 발명 실시예의 보습효과를 확인하기 위해, Corneometer CM 825 (Courage + Khazaka, Cologne, Germany)를 사용하여 보습 효과를 측정하였다. In order to confirm the moisturizing effect of the examples of the present invention, the moisturizing effect was measured using a Corneometer CM 825 (Courage + Khazaka, Cologne, Germany).
각각의 실시예에 대하여 고형분을 1%로 고정하여 추출용매로 희석하여 보습실험을 실시하였고 시료 도포 40분 후의 값을 측정하여 표 7. 에 나타내었다.For each of the examples, the solid content was fixed at 1%, and the sample was diluted with the extraction solvent. The moisture content was measured at 40 minutes after application of the sample.
실험 방법Experimental Method
20 대 여성 20 명을 대상으로 상박부 2 × 2 ㎠ , 8 구획을 물로 여러 차례 세정한 후 자극없이 수분을 제거한다. Twenty women in their twenties underwent 2 × 2 ㎠, 8 compartments on the upper abdomen and washed several times with water, and then the water was removed without stimulation.
5 분경과 후, 각각 2 구획에 대하여 측정시료 10 ㎕ 씩 점적하여 고르게 도포한다. After 5 minutes, 10 μl of the measurement sample is applied to each of the two compartments, and uniformly applied.
10 분 후, Corneometer를 이용하여 하나의 구획 당 5 회 측정한다. After 10 minutes, measure 5 times per compartment using a corneometer.
1 구획에 대하여 5 분 간격으로 6 회 측정하였고, 실내온도는 20℃, 상대습도 20%였다. One compartment was measured 6 times at intervals of 5 minutes, and the room temperature was 20 ° C and the relative humidity was 20%.
Water contents (%) = 시료 도포 후 Corneometer Value - 시료 도포 전 Corneometer Value이며, data 값은 20 명에 대한 평균치로 나타냈다.Water contents (%) = Corneometer value after application of sample - Corneometer value before application of sample, data value is average value of 20 persons.
[표 7][Table 7]
상기 결과, 발효하지 않은 추출물에 의한 보습효과도 나타났지만 본 발명의 대나무 통 발효 추출물이 일반 용기 발효 추출물, 발효를 하지 않은 추출물보다 우수한 보습효과를 나타냈음을 알 수 있었다.As a result, the moisturizing effect of the non-fermented extracts was also shown, but it was found that the fermented bamboo fermentation extract of the present invention exhibited a better moisturizing effect than the fermented extract of general containers and the fermented non-fermented extracts.
실시예 6의 정제수 추출 대나무 발효물과 실시예 7의 70% 함수 에탄올 추출 대나무 발효물은 비슷한 효과를 보였다.The purified water extracted bamboo fermented product of Example 6 and the 70% ethanol extracted bamboo fermented product of Example 7 showed similar effects.
처방예Prescription example 조제 기준 Criteria for dispensing
상기 실험예 1 내지 7 비교예 1 내지 4 에서 측정된 결과를 근거로 본 발명의 대나무 발효물인 실시예 6, 실시예 7은 비교적 비슷한 결과로 전반적으로 높은 효과를 나타내었고, 이에 따라 하기 처방은 실시예 7.을 사용하여 제조하였으며 각 성분의 함량을 중량%이다. On the basis of the results measured in Comparative Examples 1 to 4, the bamboo fermented products of Examples 6 and 7 exhibited comparatively similar results and showed high overall effectiveness. Example 7. The content of each component is% by weight.
처방예Prescription example 1. One.
실시예 7.을 함유한 화장료 중 화장수(스킨로션)의 처방 예는 다음과 같다. Examples of prescription of cosmetic lotion (skin lotion) among cosmetic compositions containing Example 7 are as follows.
<제조방법><Manufacturing Method>
제형예 1. : 11번에 2, 3, 4, 8 번을 순서대로 투입하여 교반하며 용해시킨 후, 5번을 60℃ 정도 가열하여 용해시킨 후, 10번을 투입 교반하여 11번에 투입한다. Formulation example 1: In step 11, 2, 3, 4, and 8 are added in this order and dissolved by stirring. After 5 times dissolving by heating at 60 ° C, 10 times are added and stirred at 11 times .
마지막으로 1, 6, 7, 9번을 투입하여 충분히 교반한 뒤 숙성시킨다.Finally, 1, 6, 7, and 9 are added, agitated sufficiently after stirring.
비교제형예 1. : 제형예 1.에서 실시예 7.을 제외한 것 외에는 제형예 1.과 같은 방법으로 제조한다.Comparative Formulation Example 1: Prepared in the same manner as in Formulation Example 1 except that Formulation Example 1 was omitted.
처방예Prescription example 2. 2.
실시예 7.을 함유한 화장료 중 영양로션의 처방예는 다음과 같다. Examples of prescription of nutritional lotion among cosmetics containing Example 7 are as follows.
<제조방법><Manufacturing Method>
제형예 2. : 10, 11, 13, 16을 혼합, 교반하면서 80 내지 85℃ 사이로 가열하여 제조부에 투입한 후 유화기를 작용시키고, 2, 3, 4, 5, 6, 7, 8, 9, 12를 80 내지 85℃ 사이로 가열하여 투입한 뒤 유화한다. Formulation Example 2: 10, 11, 13 and 16 were mixed and stirred while being heated to 80 to 85 ° C, charged into the production section, and then emulsified with 2, 3, 4, 5, 6, 7, , 12 is heated to between 80 and 85 캜 and then emulsified.
유화가 끝나면 교반기를 이용하여 교반하면서 50℃까지 냉각한 뒤 15번을 투입하고, 45℃까지 냉각한 뒤 14번을 투입하고, 35℃에 1번을 투입하여 25℃까지 냉각한 뒤 숙성시킨다.After the emulsification is completed, the mixture is cooled to 50 캜 with stirring using an agitator, and then the mixture is cooled to 45 캜 and then added to 35 캜. The mixture is cooled to 25 캜 and aged.
비교 제형예 2. : 제형예 2.에서 실시예 7.을 제외한 것 외에는 제형예 2.와 같은 방법으로 제조한다.Comparative Formulation Example 2: Prepared in the same manner as in Formulation Example 2, except that Formulation Example 2 is omitted.
처방예Prescription example 3 3
실시예 7.을 함유한 화장료 중 영양크림의 처방예는 다음과 같다. Examples of prescription examples of the nutritional cream among the cosmetics containing Example 7 are as follows.
<제조방법><Manufacturing Method>
제형예 3. : 10, 12, 15를 교반, 혼합하면서 80 내지 85℃ 사이로 가열하여 제조부에 투입한 후 유화기를 작용시키고, 2, 3, 4, 5, 6, 7, 8, 9, 11을 80 내지 85℃ 사이로 가열하여 투입한 뒤 유화한다. Formulation Example 3: 10, 12, and 15 were heated to between 80 and 85 캜 with stirring and mixing, and then put into a manufacturing part, and then an emulsifying agent was allowed to react and 2,3,3,4,5,6,7,8,9,11 Is heated to 80 to 85 DEG C and then emulsified.
유화가 끝나면 교반기를 이용하여 교반하면서 50℃까지 냉각한 뒤 14번을 투입하고, 45℃까지 냉각한 뒤 13번을 투입하고, 35℃까지 냉각되면 1번을 투입한 후 25℃까지 냉각한 뒤 숙성시킨다.After the emulsification is completed, the mixture is cooled to 50 ° C with stirring using an agitator, and then the mixture is cooled to 45 ° C and then cooled to 45 ° C. After cooling to 35 ° C, the mixture is cooled to 25 ° C It ages.
비교제형예 3. : 제형예 3.에서 실시예 7.을 제외한 것 외에는 제형예 3.과 같은 방법으로 제조한다.Comparative Formulation Example 3: Formulation Example 3 is prepared in the same manner as in Formulation Example 3 except that Example 7 is omitted.
처방예Prescription example 4. 4.
실시예 7.을 함유한 화장료 중 맛사지 크림의 처방예는 다음과 같다. An example of the formulation of the massage cream in the cosmetic containing Example 7 is as follows.
<제조방법><Manufacturing Method>
제형예 4. : 8, 9, 10, 12, 15를 혼합, 교반하면서 80 내지 85℃ 사이로 가열하여 제조부에 투입한 후 유화기를 작용시키고, 2, 3, 4, 5, 6, 7, 11을 80 내지 85℃ 사이로 가열하여 투입한 뒤 유화한다. Formulation Example 4: 8, 9, 10, 12, and 15 were mixed and stirred while heating to 80 to 85 ° C, Is heated to 80 to 85 DEG C and then emulsified.
유화가 끝나면 교반기를 이용하여 교반하면서 50℃ 까지 냉각한 후, 14번을 투입하고 45℃까지 냉각한 뒤 13번을 투입하고, 35℃까지 냉각되면 1번을 투입한 후 25℃까지 냉각한 뒤 숙성시킨다.After completion of the emulsification, the mixture was cooled to 50 캜 with stirring using an agitator, and then the mixture was cooled to 45 캜 and then cooled to 45 캜. After cooling to 35 캜, the mixture was cooled to 25 캜 It ages.
비교제형예 4.: 제형예 4.에서 실시예 7.을 제외한 것 외에는 제형예 4.와 같은 방법으로 제조한다.Comparative Formulation Example 4: Formulation Example 4 is prepared in the same manner as in Formulation Example 4 except that Example 7 is omitted.
처방예Prescription example 5. 5.
실시예 7.을 함유한 화장료 중 영양 에센스의 처방예는 다음과 같다. Examples of prescription of nutritional essence among cosmetics containing Example 7 are as follows.
<제조방법><Manufacturing Method>
제형예 5. : 원료물질 2, 3, 4, 5 및 6을 일정한 온도에서 균질화하여 비이온계 양친매성 지질이라 칭한다. Formulation Example 5: Raw materials 2, 3, 4, 5 and 6 are homogenized at a constant temperature to form nonionic amphipathic lipids.
상기 비이온계 양친매성 지질과 원료물질 1, 7, 8 및 14를 혼합하고, 일정한 온도에서 균질화하여 마이크로플루다이져를 통과시키고, 이어 원료물질 9를 일정한 온도에서 서서히 첨가하여 균질화한 후, 다시 마이크로플루다이져에 재차 통과시킨 뒤 10, 11, 12, 13을 투입하여 분산시켜 안정화하고 숙성시킨다.The non-ionic amphiphilic lipids and the raw materials 1, 7, 8 and 14 were mixed, homogenized at a constant temperature, passed through a microfluidizer, and then the raw material 9 was gradually added at a constant temperature to homogenize After passing again through a microfluidizer, 10, 11, 12 and 13 are added, dispersed, stabilized and aged.
비교제형예 5. : 제형예 5.에서 실시예 7.을 제외한 것 외에는 제형예 5.와 같은 방법으로 제조한다.Comparative Formulation Example 5: Prepared in the same manner as in Formulation Example 5 except that Formulation Example 5 was omitted.
처방예Prescription example 6 6
실시예 7.을 함유한 화장료 중 유화형 화운데이션의 처방예는 다음과 같다.An example of the formulation of the emulsion type foundation among the cosmetics containing Example 7 is as follows.
<제조방법><Manufacturing Method>
제형예 6. : 9, 10, 11, 12, 13, 14, 15, 17을 혼합, 교반하면서 80 내지 85℃ 사이로 가열하여 제조부에 투입한 후 유화기를 작용시키고, 2, 3, 4, 5, 6, 7, 8을 80 내지 85℃ 사이로 가열하여 투입한 뒤 유화한다. Formulation Example 6: 9, 10, 11, 12, 13, 14, 15, and 17 were heated to 80 to 85 ° C while stirring and mixing, , 6, 7, and 8 are heated to between 80 and 85 캜 and then emulsified.
유화가 끝나면 교반기를 이용하여 교반하면서 45℃ 까지 냉각한 뒤 16번을 투입하고, 35℃까지 냉각한 뒤 1번을 투입하고 25℃까지 냉각하여 숙성시킨다.After the emulsification is completed, the mixture is cooled to 45 ° C with stirring using an agitator, and then 16 times. After cooling to 35 ° C, the mixture is cooled to 25 ° C and aged.
비교제형예 6. : 제형예 6.에서 실시예 7.을 제외한 것 외에는 제형예 6.과 같은 방법으로 제조한다.Comparative Formulation Example 6: The same procedure as in Formulation Example 6 was carried out except that in Formulation Example 6, Example 7 was omitted.
시험예Test Example 1. 아토피 개선 효과 확인실험 1. Atopy test
제형예 3.과 비교 제형예 3.의 영양크림에 대한 피부 도포시, 아토피 개선 효과를 확인하기 위하여 다음과 같은 임상 확인 실험을 하였다.The following clinical confirmation tests were carried out to confirm the effect of atopic dermatitis on the nutritional cream of Formulation Example 3 and Comparative Formulation Example 3 when applied to the skin.
5 내지 30세의 아토피 환자로서, 2년 이상 아토피 피부염을 앓고 있는 환자 중 20 여명에 대하여 아토피 개선 효과를 조사하여 표 8에 나타내었다.Table 8 shows the atopy improvement effect of about 20 out of the patients suffering from atopic dermatitis for 2 years or more as a 5 to 30 year old atopic patient.
동일인에게 왼쪽 손에는 제형예 3.의 영양 크림을, 복부 오른쪽 손에는 비교제형예 3.의 영양크림을 매일 저녁 세정 후, 피부에 1일 1회 60일간 도포한 후 아토피 상태 개선을 확인하기 위하여 아토피 상태 개선 정도를 측정하였다.To the same person, the nutritional cream of Formulation Example 3 was applied to the left hand, and the nutritional cream of Comparative Formulation Example 3 was applied to the right hand of the abdomen every evening, and the skin was applied to the skin once a day for 60 days to confirm improvement of atopic condition The degree of atopic condition improvement was measured.
[표 8][Table 8]
상기 조사 결과와 같이 실시예 7.을 첨가하여 제조한 제형예 3.이 실시예 7.이 첨가되지 않은 비교제형예 3.보다 피부 개선 효과가 우수하다는 것을 알 수 있다. It can be seen that Formulation Example 3 prepared by adding Example 7, as in the above-mentioned investigation, is superior to Comparative Formulation Example 3 in which Example 7 is not added.
이러한 결과는 본 발명에서 아토피 피부에 유용한 생약의 선택과 대나무 통 용기에서 발효시킴으로써, 대나무에 포함된 약재 성분의 추출과 천연의 재료인 대나무 통을 발효용기로 사용하여, 대나무 자체가 가지고 있는 영양분에 의하여 별도의 영양 배지 없이도 발효가 가능하고, 별도의 배양기를 사용하지 아니하여 2차 오염의 우려도 없는 것이다.These results indicate that the selection of medicinal herbs useful for atopic skin and the fermentation of bamboo containers in the present invention enable extraction of the medicinal ingredients contained in bamboo and the use of natural bamboo containers as fermentation containers, Therefore, it is possible to ferment without separate nutrient medium, and there is no fear of secondary contamination because no separate incubator is used.
본 발명의 대나무 통 발효 추출물은 아토피 피부 개선 효과가 뛰어나며 인체에 무해한 것이므로, 화장료의 원료로서 매우 유용한 발명인 것이다. The bamboo fermented extract of the present invention is an extremely useful invention as a raw material for cosmetics since it has an excellent atopic skin improving effect and is harmless to human body.
본 발명의 상세한 설명은 단지 본 발명의 예시적인 것으로서, 이는 단지 본 발명을 설명하기 위한 목적에서 사용된 것이지 의미 한정이나 특허청구범위에 기재된 본 발명의 범위를 제한하기 위하여 사용된 것은 아니다. The detailed description of the invention is merely exemplary of the invention, which is used for the purpose of describing the invention only and is not used to limit the scope of the invention as defined in the claims or the claims.
그러므로 본 기술 분야의 통상의 지식을 가진 자라면 이로부터 다양한 변형 및 균등한 타 실시예가 가능하다는 점을 이해할 것이다. Therefore, those skilled in the art will appreciate that various modifications and equivalent embodiments are possible without departing from the scope of the present invention.
따라서 본 발명의 진정한 기술적 보호 범위는 첨부된 특허청구범위의 기술적 사상에 의해 정해져야 할 것이다.Accordingly, the true scope of the present invention should be determined by the technical idea of the appended claims.
Claims (7)
상기 혼합 성분을 용매로 추출 후 0.45 ㎛의 여과지로 여과한 후 약 60℃ 전, 후의 온도에서 일정량 감압 농축하는 공정,
상기 추출물을 대나무 통 용기에 첨가하여 약 110 내지 130℃에서 멸균하고 냉각한 후 효모균(Saccharomyces cerevisiae)을 접종하고, 20 내지 30℃에서 1 내지 7일 동안 숙성 발효시키는 공정,
상기의 대나무 통 발효 추출물을 0.45 ㎛의 여과지로 여과한 후, 액상으로 0.1 내지 10중량% 범위로 화장료에 첨가하는 것을 특징으로 아토피 피부 개선용 화장료 조성물의 제조방법.5 to 22% by weight of fibrils having anti-inflammatory, moisturizing and free radical scavenging effects, 1 to 15% by weight of white paper, 1 to 15% by weight of cilantro, 1 to 15% by weight of Puerariae, 5 to 22% By weight, 1 to 15% by weight of peanuts, 5 to 40% by weight of topsoil, 1 to 15% by weight of magazine, 1 to 15% by weight of doze, 1 to 15%
The mixed components are extracted with a solvent, filtered through a filter paper having a pore size of 0.45 mu m, and concentrated under reduced pressure at a temperature of about 60 DEG C before and after the filtration.
The extract was added to a bamboo vial, sterilized at about 110 to 130 DEG C, cooled, and the yeast ( Saccharomyces cerevisiae ), aging fermentation at 20 to 30 DEG C for 1 to 7 days,
Wherein the fermented bamboo extract is filtered through a filter paper having a pore size of 0.45 μm and then added to the cosmetic composition in a liquid form in an amount of 0.1 to 10% by weight.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120027060A KR101412500B1 (en) | 2012-03-16 | 2012-03-16 | Cosmetic composition for improving atopic skin comprising herb extract fermented in bamboo cylinder and manufacturing method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120027060A KR101412500B1 (en) | 2012-03-16 | 2012-03-16 | Cosmetic composition for improving atopic skin comprising herb extract fermented in bamboo cylinder and manufacturing method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130105003A true KR20130105003A (en) | 2013-09-25 |
KR101412500B1 KR101412500B1 (en) | 2014-06-26 |
Family
ID=49453744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120027060A KR101412500B1 (en) | 2012-03-16 | 2012-03-16 | Cosmetic composition for improving atopic skin comprising herb extract fermented in bamboo cylinder and manufacturing method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101412500B1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104013911A (en) * | 2014-05-27 | 2014-09-03 | 上海市中医医院 | Tea and golden yellow past-containing medicament for treating phlebitis |
CN106880561A (en) * | 2015-12-11 | 2017-06-23 | 高丽雅娜化妆品股份有限公司 | The cosmetic composition containing black bamboo extract for adjusting skin temperature |
CN108785167A (en) * | 2018-07-11 | 2018-11-13 | 王培战 | Root of Dahurain angelica liquid bio fermentate and preparation method thereof and the purposes in terms of cosmetics |
CN109207550A (en) * | 2018-11-22 | 2019-01-15 | 哈尔滨氧态健康科技股份有限公司 | A kind of preparation method of peony seeds polypeptide |
KR102149223B1 (en) * | 2019-12-13 | 2020-08-28 | 주식회사 인투바이오 | Cosmetic composition for skin whitening containing the fermented complex natural extracts |
KR20210144279A (en) * | 2020-05-22 | 2021-11-30 | 담양죽순 영농조합법인 | Method for antibiotic and cosmetic compositions containing bamboo multi complex and the cosmetic composition thereby |
KR20230131504A (en) * | 2022-03-03 | 2023-09-14 | 코스맥스 주식회사 | Composition comprising microorganism fermented oil of traditional herbal medicines and its use for improving skin condition |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102545060B1 (en) * | 2023-01-09 | 2023-06-20 | 주식회사 제이앤제이파머텍 | Cosmetic composition for acne improvement containing fermented extracts from natural materials as active ingredients |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100472052B1 (en) * | 2003-02-24 | 2005-02-21 | (주)애지바이오화장품 | Cosmetic composition using fermentation of natural herb medicine |
KR101051362B1 (en) * | 2007-08-31 | 2011-07-22 | (주)콤비메드 | Atopic Dermatitis Treatment and / or Prevention Composition Comprising Herbal Fermentation Products |
KR101081913B1 (en) * | 2009-02-02 | 2011-11-09 | 한불화장품주식회사 | Skin agent composition containing the oriental-herb extracts using microbial fermentation |
-
2012
- 2012-03-16 KR KR1020120027060A patent/KR101412500B1/en active IP Right Grant
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104013911A (en) * | 2014-05-27 | 2014-09-03 | 上海市中医医院 | Tea and golden yellow past-containing medicament for treating phlebitis |
CN106880561A (en) * | 2015-12-11 | 2017-06-23 | 高丽雅娜化妆品股份有限公司 | The cosmetic composition containing black bamboo extract for adjusting skin temperature |
CN106880561B (en) * | 2015-12-11 | 2020-04-14 | 高丽雅娜化妆品股份有限公司 | Cosmetic composition containing black bamboo extract for regulating skin temperature |
CN108785167A (en) * | 2018-07-11 | 2018-11-13 | 王培战 | Root of Dahurain angelica liquid bio fermentate and preparation method thereof and the purposes in terms of cosmetics |
CN109207550A (en) * | 2018-11-22 | 2019-01-15 | 哈尔滨氧态健康科技股份有限公司 | A kind of preparation method of peony seeds polypeptide |
KR102149223B1 (en) * | 2019-12-13 | 2020-08-28 | 주식회사 인투바이오 | Cosmetic composition for skin whitening containing the fermented complex natural extracts |
KR20210144279A (en) * | 2020-05-22 | 2021-11-30 | 담양죽순 영농조합법인 | Method for antibiotic and cosmetic compositions containing bamboo multi complex and the cosmetic composition thereby |
KR20230131504A (en) * | 2022-03-03 | 2023-09-14 | 코스맥스 주식회사 | Composition comprising microorganism fermented oil of traditional herbal medicines and its use for improving skin condition |
CN116807934A (en) * | 2022-03-03 | 2023-09-29 | 科丝美诗株式会社 | Composition of microbial fermentation oil comprising Korean medicinal material and its use in improving skin condition |
Also Published As
Publication number | Publication date |
---|---|
KR101412500B1 (en) | 2014-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101412500B1 (en) | Cosmetic composition for improving atopic skin comprising herb extract fermented in bamboo cylinder and manufacturing method thereof | |
JP6077554B2 (en) | Wrapping fermentation method using medicinal flowers and skin external preparation composition using the method | |
KR101146206B1 (en) | Cosmetic Composition And Composition of Skin External Application | |
KR20210038369A (en) | Detergent composition comprising oriental medical extract for preventing alopecia and promoting hair growth and method for producing the same | |
KR101387308B1 (en) | Skin whitening composition by using of dendropanax morbifera ferment extract | |
KR101744103B1 (en) | Composition for preventing hair loss and promoting hair growth and mathod for preparing the same | |
KR101284656B1 (en) | Cosmetic Composition | |
KR101829892B1 (en) | A cosmetic composition comprising fraxinus rhynchophylla extract and calystegia soldanella extract | |
KR20090005479A (en) | Hair growth composition | |
CN102988264A (en) | Ginkgo leaf freckle removing whitening cream and preparation method thereof | |
KR102004366B1 (en) | A cosmetic composition comprising centipeda minima extract | |
KR20130015339A (en) | Cream composition for treating acne | |
KR100975135B1 (en) | Cosmetic composition containing herbal combination medicine having antioxidant effect | |
CN105997827A (en) | Compound camellia oil moisturizing liquid and preparation method thereof | |
KR20190003268A (en) | Cpmposition for care of dermatic disease comprinsing plant extract | |
KR101300701B1 (en) | The cosmetics to have an atopic dermatitis improvement efficacy making method besides | |
KR102002894B1 (en) | Cosmetic composition containing the complex natural extracts | |
CN103041042B (en) | Tibetan medicine composition and application of composition in anti-off hair products | |
KR102113645B1 (en) | A cosmetic composition for preventing hair loss and promoting hair growth containing spicule powder and natural extract | |
KR101332215B1 (en) | Cosmetic composition containing fermentated complex of extracts with cryptomeria japonica and nelumbo nucifera for acne improvement and enhancing immune system | |
KR100999870B1 (en) | Pharmaceutical composition for preventing and treating allergic skin diseases, containing Echo and Elm extract as active ingredients | |
KR100991399B1 (en) | Pharmaceutical composition for the prevention and treatment of allergic skin diseases, which contains Eungseongcho, Geumchocho, Chajeoncho, Elm and upper leaf mixed extract as active ingredients | |
KR101829891B1 (en) | A cosmetic composition comprising osmanthus asiaticus extract and clematis apiifolia extract | |
CN115429725B (en) | Cosmetic composition for antioxidation, anti-inflammatory and skin tranquilization | |
KR100903827B1 (en) | Handmade herbal soap and its manufacturing method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20120316 |
|
PA0201 | Request for examination | ||
N231 | Notification of change of applicant | ||
PN2301 | Change of applicant |
Patent event date: 20130617 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20131030 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20140524 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20140620 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20140620 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20170602 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20170602 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20180105 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20180105 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20191212 Year of fee payment: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20191212 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20201214 Start annual number: 8 End annual number: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20220323 Start annual number: 9 End annual number: 9 |
|
PR1001 | Payment of annual fee |
Payment date: 20230308 Start annual number: 10 End annual number: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20240312 Start annual number: 11 End annual number: 11 |